CA3088138A1 - Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (fap-alpha) - Google Patents

Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (fap-alpha) Download PDF

Info

Publication number
CA3088138A1
CA3088138A1 CA3088138A CA3088138A CA3088138A1 CA 3088138 A1 CA3088138 A1 CA 3088138A1 CA 3088138 A CA3088138 A CA 3088138A CA 3088138 A CA3088138 A CA 3088138A CA 3088138 A1 CA3088138 A1 CA 3088138A1
Authority
CA
Canada
Prior art keywords
group
co2h
fap
compound
6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3088138A
Other languages
English (en)
French (fr)
Inventor
Xing Yang
Sridhar Nimmagadda
Steven Rowe
Stephanie SLANIA
Martin G. Pomper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66247306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3088138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA3088138A1 publication Critical patent/CA3088138A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3088138A 2017-10-23 2018-10-23 Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (fap-alpha) Pending CA3088138A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575607P 2017-10-23 2017-10-23
US62/575,607 2017-10-23
PCT/US2018/057086 WO2019083990A2 (en) 2017-10-23 2018-10-23 IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)

Publications (1)

Publication Number Publication Date
CA3088138A1 true CA3088138A1 (en) 2019-05-02

Family

ID=66247306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3088138A Pending CA3088138A1 (en) 2017-10-23 2018-10-23 Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (fap-alpha)

Country Status (12)

Country Link
US (5) US20200330624A1 (enExample)
EP (1) EP3700580A4 (enExample)
JP (2) JP2021500373A (enExample)
KR (2) KR102764076B1 (enExample)
CN (2) CN111511408A (enExample)
AU (2) AU2018355222B2 (enExample)
BR (1) BR112020008011A2 (enExample)
CA (1) CA3088138A1 (enExample)
EA (1) EA202090776A1 (enExample)
IL (1) IL274088A (enExample)
MX (2) MX2020004807A (enExample)
WO (1) WO2019083990A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
SG11202005563YA (en) * 2017-12-15 2020-07-29 Praxis Biotech LLC Inhibitors of fibroblast activation protein
MX2020008271A (es) * 2018-02-06 2020-11-09 Univ Heidelberg Inhibidor de fap.
JP7161044B2 (ja) 2018-10-17 2022-10-25 パーデュー・リサーチ・ファウンデーション 線維症における線維芽細胞活性化タンパク質（ｆａｐ）を標的とする撮像法および治療法
WO2020132661A2 (en) 2018-12-21 2020-06-25 Praxis Biotech LLC Inhibitors of fibroblast activation protein
EP3997104A1 (en) 2019-07-08 2022-05-18 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
IL289675B1 (en) 2019-07-08 2025-09-01 3B Pharmaceuticals Gmbh Compounds comprising a protein ligand for fibroblast activation and their use
CN114901315B (zh) * 2019-09-17 2025-04-29 普渡研究基金会 癌症和其他纤维化和炎性疾病的成纤维细胞活化蛋白(fap)靶向的成像和治疗
US20230100158A1 (en) * 2020-01-31 2023-03-30 Purdue Research Foundation Fibroblast activation protein (fap) - targeted antifibrotic therapy
PL3891138T3 (pl) 2020-02-12 2022-05-02 Philochem Ag Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu
WO2021224438A1 (en) 2020-05-07 2021-11-11 Institut Curie Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
WO2021234181A1 (en) * 2020-05-22 2021-11-25 Universität Heidelberg Use of fap inhibitor in a method of diagnosis
CN112138175A (zh) * 2020-09-01 2020-12-29 上海市质子重离子临床技术研发中心 一种放射性核素99mTc标记FAPI的化合物的制备方法
CN114790194B (zh) * 2020-12-21 2024-03-26 苏州药明博锐生物科技有限公司 成纤维细胞活化蛋白抑制剂
EP4050018A1 (en) * 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
AU2022205523A1 (en) * 2021-01-07 2023-07-13 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
JP7651785B2 (ja) * 2021-02-10 2025-03-27 烟台藍納成生物技術股▲ふん▼有限公司 切断型エバンスブルー修飾線維芽細胞活性化タンパク質阻害剤及びその調製方法と応用
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
KR20230145162A (ko) 2021-02-12 2023-10-17 필로켐 아게 표적 전달 이용을 위한 2가 섬유모세포 활성화 단백질 리간드
EP4043452A1 (en) 2021-02-12 2022-08-17 Philochem AG Bivalent fibroblast activation protein ligands for targeted delivery applications
CN113105432B (zh) * 2021-03-30 2022-03-04 上海交通大学医学院附属仁济医院 一种碳-11（11c）放射性药物及其制备方法和应用
EP4313049A1 (en) * 2021-04-02 2024-02-07 The Johns Hopkins University Heterobivalent and homobivalent agents targeting fibroblast activation protein alpha and/or prostate-specific membrane antigen
CN113277989B (zh) * 2021-04-27 2022-05-31 中南大学湘雅医院 一种68Ga标记的分子探针、制备方法及其应用
WO2022241506A1 (en) * 2021-05-19 2022-11-24 Ferronova Pty Ltd Mapping nanoparticles
CN113527266A (zh) * 2021-06-23 2021-10-22 上海健康医学院 一种靶向fap的双氧水响应的前药及其制备方法与应用
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
EP4122499A1 (en) * 2021-07-23 2023-01-25 3B Pharmaceuticals GmbH Fibroblast activation protein inhibitors and use thereof
TW202320805A (zh) * 2021-08-18 2023-06-01 美商杜夫特學院信託管理公司 用於pet造影之選擇性靶向纖維母細胞活化蛋白之放射性氟標誌試劑
CN113880810B (zh) * 2021-09-24 2023-02-28 厦门大学 一种核素标记的配合物及其制备方法和应用
MX2024004077A (es) 2021-10-04 2024-04-18 Philochem Ag Ligandos de proteina de activacion de fibroblastos radioetiquetados.
TW202317541A (zh) 2021-10-28 2023-05-01 行政院原子能委員會核能研究所 一種靶向成纖維細胞活化蛋白之化合物或其鹽，其製備方法及其用途
WO2023081301A1 (en) * 2021-11-05 2023-05-11 On Target Laboratories, LLC Fibroblast activation protein targeted dyes their related uses
US20250177582A1 (en) 2022-01-30 2025-06-05 Philochem Ag High-affinity ligands of fibroblast activation protein for targeted delivery applications
EP4483905A1 (en) * 2022-02-22 2025-01-01 Osaka University Radiolabeled fap-alpha-affinity compound and use thereof
US20250263393A1 (en) * 2022-04-21 2025-08-21 Shanghai Sinotau Biotech. Co., Ltd Fap inhibitors
WO2023222558A1 (en) 2022-05-14 2023-11-23 Zounek Alexis Nikolai Precursor and theranostic radiotracer with improved tumor retention
CN115304582B (zh) * 2022-07-20 2023-05-12 北京法伯新天医药科技有限公司 FAP-α特异性肿瘤诊断显像剂
IL318543A (en) * 2022-07-28 2025-03-01 Ratio Therapeutics Inc Protein-targeted compositions for activating fibroblasts and methods for using them
CN115368342B (zh) * 2022-08-24 2024-01-23 西南医科大学附属医院 成纤维细胞活性蛋白抑制剂、其放射性核素标记物及制备方法和应用
CN119816493A (zh) 2022-09-06 2025-04-11 菲罗化学股份公司 用于靶向递送应用的多价成纤维细胞激活蛋白配体
EP4342890A1 (en) 2022-09-21 2024-03-27 Erasmus University Rotterdam Medical Center Platform and scaffold for fap targeting agents
JP2025532104A (ja) * 2022-09-23 2025-09-29 ヌクリディウム アクチェンゲゼルシャフト 高純度銅放射性医薬組成物ならびにその診断および治療用途
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
CN117883585A (zh) * 2022-10-14 2024-04-16 无锡诺宇医药科技有限公司 靶向成纤维细胞活化蛋白的药物及其应用
EP4653451A1 (en) * 2023-02-10 2025-11-26 Chengdu New Radiomedicine Technology Co., Ltd. Polypeptide compound and use thereof
CN120957982A (zh) * 2023-05-08 2025-11-14 江苏恒瑞医药股份有限公司 靶向成纤维细胞活化蛋白的配体
WO2025029608A1 (en) * 2023-07-28 2025-02-06 Ratio Therapeutics, Inc. Fibroblast activation protein-targeted compositions and methods of use thereof
WO2025046043A1 (en) 2023-08-31 2025-03-06 Stichting Radboud Universitair Medisch Centrum Endometriosis tracer
WO2025063849A2 (en) 2023-09-21 2025-03-27 Erasmus University Medical Center Rotterdam Dimeric fap targeting agents
WO2025125335A1 (en) 2023-12-13 2025-06-19 Radiovaxx Gmbh Cytotoxic or radiopharmaceutical compound with sulfur fluoride exchange group
WO2025125621A1 (en) 2023-12-14 2025-06-19 Radiovaxx Gmbh Cancer-associated protein-targeted strong or covalently binding precursor compounds and radiotracers
WO2025146433A1 (en) 2024-01-05 2025-07-10 Radiovaxx Gmbh Precursor and theranostic radiotracer with prolonged tumor retention
CN118063689B (zh) * 2024-01-26 2025-01-28 锐康九域(厦门)医药科技有限公司 成纤维细胞激活蛋白-α响应水解致电荷翻转的聚合物-药物偶联物及其制备方法和应用
CN118271393B (zh) * 2024-05-31 2024-09-03 中国药科大学 一种靶向fap的二聚化合物及其探针和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125227A2 (en) * 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
CA2694266C (en) * 2007-06-26 2016-06-14 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
DK3222615T3 (da) * 2008-08-01 2022-06-20 Univ Johns Hopkins Psma-bindende stoffer og anvendelser deraf
CN102203061A (zh) * 2008-09-25 2011-09-28 分子制药洞察公司 选择性seprase抑制剂
WO2016149188A1 (en) * 2015-03-13 2016-09-22 The Johns Hopkins University 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
PL3964502T3 (pl) * 2009-03-19 2024-10-28 The Johns Hopkins University Związki do kierunkowania w psma i ich zastosowania
US9346814B2 (en) * 2012-01-17 2016-05-24 Universiteit Antwerp FAP inhibitors
US20150320892A1 (en) * 2012-06-29 2015-11-12 Ge Healthcare Limited Imaging fibrosis
WO2014028057A1 (en) * 2012-08-15 2014-02-20 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
WO2015114166A2 (en) * 2014-02-03 2015-08-06 Philochem Ag Targeted drug conjugates
WO2016065142A2 (en) * 2014-10-22 2016-04-28 The Johns Hopkins University New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
US10857246B2 (en) * 2015-06-01 2020-12-08 The Johns Hopkins University Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
MX2020008271A (es) 2018-02-06 2020-11-09 Univ Heidelberg Inhibidor de fap.

Also Published As

Publication number Publication date
US12115233B2 (en) 2024-10-15
KR20240162157A (ko) 2024-11-14
EA202090776A1 (ru) 2020-07-27
EP3700580A2 (en) 2020-09-02
US20200330624A1 (en) 2020-10-22
KR20200063230A (ko) 2020-06-04
US20240293584A1 (en) 2024-09-05
AU2024203249A1 (en) 2024-06-06
IL274088A (en) 2020-06-30
CN116617420A (zh) 2023-08-22
MX2023013164A (es) 2023-11-23
WO2019083990A3 (en) 2019-06-13
AU2018355222A1 (en) 2020-04-30
JP2021500373A (ja) 2021-01-07
MX2020004807A (es) 2020-10-05
US20250186628A1 (en) 2025-06-12
AU2018355222B2 (en) 2024-10-03
JP2024109682A (ja) 2024-08-14
KR102764076B1 (ko) 2025-02-05
WO2019083990A2 (en) 2019-05-02
EP3700580A4 (en) 2021-06-23
BR112020008011A2 (pt) 2020-10-27
US11938201B2 (en) 2024-03-26
US20230364274A1 (en) 2023-11-16
CN111511408A (zh) 2020-08-07
US20250235565A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
US12115233B2 (en) Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α)
US20240382629A1 (en) Heterobivalent and homobivalent agents targeting fibroblast activation protein alpha and/or prostate-specific membrane antigen
EP3433238B1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
JP7030061B2 (ja) 炭酸脱水酵素ｉｘを標的にする核造影および放射性治療剤ならびにそれらの使用
US20180133348A1 (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase ix and uses thereof
CA3024097C (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase ix and uses thereof
HK1259764B (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
HK40006359A (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase ix and uses thereof
HK40006359B (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase ix and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231023